http://orcid.org/0000-0003-4508-5469
Figures
Abstract
Background
We aimed to establish the prevalence of amphotericin B deoxycholate (AmBd)-related toxicities among South African patients with cryptococcosis and determine adherence to international recommendations to prevent, monitor and manage AmBd-related toxicities.
Methods
Clinical data were collected from cases of laboratory-confirmed cryptococcosis at 25 hospitals, October 2012 –February 2013. Anemia was defined as hemoglobin (Hb) concentration <10 g/dl, hypokalemia as serum potassium (K) <3.4 mEq/L and nephrotoxicity as an increase in serum creatinine (Cr) to >1.1 times the upper limit of normal. To determine adherence to toxicity prevention recommendations, we documented whether baseline Hb, K and Cr tests were performed, whether pre-emptive hydration and IV potassium chloride (KCl) was administered prior to 80% and 60% of AmBd doses and whether daily oral KCl supplementation was given ≥60% of the time. To determine adherence to monitoring recommendations, we ascertained whether a daily fluid chart was completed, Hb was monitored weekly and K or Cr were monitored bi-weekly.
Results
Of 846 patients, clinical data were available for 76% (642/846), 82% (524/642) of whom received AmBd. Sixty-four per cent (n = 333) had documented baseline laboratory tests, 40% (n = 211) were given pre-emptive hydration and 14% (n = 72) and 19% (n = 101) received intravenous and oral KCl. While on AmBd, 88% (n = 452) had fluid monitoring; 27% (n = 142), 45% (n = 235) and 44% (n = 232) had Hb, K and Cr levels monitored. Toxicities developed frequently during treatment: anemia, 16% (86/524); hypokalemia, 43% (226/524) and nephrotoxicity, 32% (169/524).
Author Summary
Amphotericin B deoxycholate (AmBd)-based induction therapy is recommended for treatment of HIV-associated cryptococcosis in South Africa. We reviewed 846 patient records to determine adherence to World Health Organization (WHO) recommendations to prevent, monitor and manage AmBd-related toxicities and determine the prevalence of such toxicities.
Citation: Meiring S, Fortuin-de Smidt M, Kularatne R, Dawood H, Govender NP, GERMS-SA (2016) Prevalence and Hospital Management of Amphotericin B Deoxycholate-Related Toxicities during Treatment of HIV-Associated Cryptococcal Meningitis in South Africa. PLoS Negl Trop Dis 10(7): e0004865. https://doi.org/10.1371/journal.pntd.0004865
Editor: Pamela L. C. Small, University of Tennessee, UNITED STATES
Received: March 29, 2016; Accepted: June 29, 2016; Published: July 28, 2016
Copyright: © 2016 Meiring et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Data are available from the corresponding author or from Dr. Vanessa Quan, head of the GERMS-SA surveillance programme at the National Institute for Communicable Diseases; as data contains information that could compromise patient confidentiality. Data will be made available on request to those who meet criteria for access to confidential data. Dr. Quan can be contacted at the following address, vanessaq@nicd.ac.za.
Funding: Development of this publication was supported by the National Institute for Communicable Disease, a division of the National Health Laboratory Services in South Africa and partially funded by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC) under the terms of [5U2GPS001328]. The PEPFAR funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: NPG has received speaker honoraria/ travel grants from Pfizer, Astellas and MSD (Pty) Ltd; has been the recipient of an investigator-initiated research grant from Pfizer for unrelated work; has provided educational materials for TerraNova; and has acted a temporary consultant for Fujifilm Pharmaceuticals. HD has received honoraria from Pfizer-South Africa, Novartis-South Africa and MSD-South Africa for speaking engagements; and travel grants from Novartis-South Africa and Myalan-South Africa. The remaining authors have no conflicts of interest to declare.
Introduction
Cryptococcus neoformans is a leading cause of meningitis among severely immunocompromised HIV-infected adults and even with amphotericin B-based therapy, the mortality is high [1–3]. Advanced HIV disease at diagnosis (CD4+ T-lymphocyte (CD4) count <200 cells/μl), high cerebrospinal fluid (CSF) fungal burden, sub-optimal management of cryptococcal meningitis (CM), delayed initiation of antiretroviral treatment (ART) and the presence of co-morbid conditions such as tuberculosis all contribute to the high case-fatality ratio (CFR) [4–6].
Amphotericin B deoxycholate (AmBd), in combination with fluconazole, is recommended as first-line induction therapy for the treatment of CM in South Africa (AmBd 1 mg/kg/day plus oral fluconazole 800 mg daily). Since publication of recommendations by the South African HIV Clinicians’ Society (SAHIVCS) in 2007, the proportion of patients treated with AmBd-based therapy for CM has increased from 30% to 80% [7–10]. Despite this increase, there has been no associated decrease in the in-hospital CFR which has remained between 31% and 34% since 2007[11, 12].
AmBd is rapidly fungicidal against Cryptococcus; however, the antifungal agent has several adverse effects due to its binding with cholesterol in human cell membranes [13, 14]. The most common adverse events include nephrotoxicity, hypokalemia, hypomagnesemia, anemia, febrile reactions and chemical phlebitis. An observational study from Kenya reported nephrotoxicity in 59%, hypokalemia in 93%, and hypomagnesaemia in 80% of 70 patients with CM treated with AmBd[15]. In clinical trial settings with standardized pre-hydration and electrolyte supplementation regimens, 10% of patients still develop nephrotoxicity and 6% develop hypokalemia [16–18]. A recent study reported improved 30-day survival following proactive fluid and electrolyte management of patients with CM treated with AmBd.[19] Following recommendations by the WHO, South African guidelines were modified to include a minimum package of interventions to prevent, monitor and treat AmBd-related toxicities [7, 20].
Currently, there are few real-world data on the prevalence of AmBd toxicities and the use of interventions to prevent, monitor and treat these toxicities in the context of HIV-associated CM. In this observational study conducted at 25 sentinel South African hospitals, we aimed to establish the prevalence of AmBd-related toxicities among patients with CM, to determine physician awareness of the recommendations and to determine if these recommendations were being followed.
Methods
Study setting and design
This prospective, observational cross-sectional study was nested within national, laboratory-based, population-based surveillance for cryptococcosis in South Africa, conducted by the National Institute for Communicable Diseases (GERMS-SA)[21]. A case of cryptococcosis was defined as a person who was seen at a South African healthcare facility with a positive CSF India ink test, a positive cryptococcal antigen test (on CSF or serum) or culture of Cryptococcus from any anatomical specimen. If a subsequent specimen from the same person tested positive for any of the aforementioned tests >30 days after the first positive specimen, this was considered as a case of recurrent disease and included in the study. At 25 enhanced surveillance (ES) sites in nine provinces, clinical data (such as HIV infection status, CD4 count, ART use, mental status at diagnosis [assessed by using the Glasgow Coma Scale (GCS) score], antifungal treatment and in-hospital outcome) were collected through medical record review and/or interview. The ES sites are large hospitals in urban areas; 11 of the 25 facilities were categorized as academic hospitals (i.e. directly linked to a university medical school and conducted training of medical students and specialists). From October 2012 through February 2013, additional laboratory and clinical data were collected from adults who were prescribed AmBd in hospital and gave informed consent for both surveillance and this nested study.
Study definitions
AmBd-related toxicities.
Patients with anemia, hypokalemia or nephrotoxicity that was diagnosed prior to initiation of AmBd were excluded from prevalence calculations. Toxicities were determined according to the Division of AIDS grading criteria[22]. Anemia was defined as a hemoglobin (Hb) <10 g/dL, hypokalemia was defined as a serum potassium (K) <3.4 mEq/L and nephrotoxicity was defined as a serum creatinine (Cr) level that increased to >1.1 times the upper limit of normal (1.1 mg/dL). Toxicities were reported as potentially life-threatening (grade 4 of the severity of adverse events grading for laboratory tests) if Hb was <6.5 g/dL, serum K was <2.0 mEq/L and serum Cr increased to ≥3.5 times the upper limit of normal (1.1 mg/dL)[22]. No data were collected on thrombophlebitis.
Adherence to recommendations for prevention of AmBd-related toxicities.
Four laboratory or clinical parameters were reviewed: (1) baseline Hb, K and Cr tests performed in the week prior to starting AmBd; (2) intravenous (IV) pre-emptive hydration with 1L of 0.9% saline administered prior to each AmBd dose; (3) 1 ampule of IV potassium chloride (KCl) administered prior to each AmBd dose and (4) oral KCl supplementation administered daily whilst the patients were receiving AmBd. For each parameter, optimal adherence was arbitrarily defined as: (1) all baseline tests were performed in the week prior to starting AmBd, (2) 1L of 0.9% saline was administered prior to at least 80% of AmBd doses, (3) IV KCl supplementation was administered prior to at least 60% of AmBd doses and (4) oral KCl was administered for at least 60% of the days during which the patient was on AmBd.
Adherence to recommendations for monitoring for AmBd-related toxicities.
Four parameters were reviewed and while patients were on AmBd treatment, optimal adherence was defined as: (1) a completed daily fluid input/output chart; (2) weekly Hb tests; (3) biweekly serum K and (4) biweekly serum Cr tests.
Physician interviews
From October 2012 through June 2013, we interviewed physicians who were currently involved in the daily management of patients with cryptococcosis at the 25 ES sites. We approached at least 4 physicians at each of the ES sites to participate in the study. A standardized study questionnaire was used to determine the knowledge and behavior of physicians with regard to prevention and monitoring of AmBd toxicities and the general in-hospital management of cryptococcosis.
Statistical analysis
Data analysis was performed using Stata version 11.2 (StataCorp, College Station, Texas). Univariate and multivariable analyses were conducted to determine the factors that were associated with in-hospital outcome. The logistic regression model included ES site category [academic vs. non-academic], sex, CD4 count, ART use, mental status at diagnosis and whether or not recommendations to prevent and monitor AmBd-related toxicities were followed optimally. P values <0.05 were considered significant.
Ethics
Approval to conduct cryptococcal disease surveillance was obtained from the following university-affiliated Human Research Ethics Committees: University of the Witwatersrand (WITS) (M081117); University of Cape Town (UCT) (115/2009); Stellenbosch University (SU) (N04/01/001) and University of KwaZulu-Natal (UKZN) (BF130/11). Approval for the nested study was obtained from SU and UKZN as amendments to the cryptococcal disease surveillance protocol and as a new study with unique references from WITS (M120845) and UCT (482/2012). Written informed consent was obtained from all interviewed patients and clinicians.
Results
Cases of cryptococcosis at ES sites
During the five-month study period, of 846 unique episodes of cryptococcosis, clinical data were available for 642 (76%). (Fig 1) There were no significant differences in ES site category, sex or age for patients with available data compared to those with missing data. Of those with available data, 45% were female (288/640, sex unknown for 2 cases); all patients were HIV-infected; and 78% (351/452, CD4 count not done for 190 cases) had a CD4 count <100 cells/μl at diagnosis. Thirty-seven per cent (240/642) were on ART at diagnosis. Eighty-two per cent (524/642) of the patients were treated with AmBd with no significant difference by ES site category. (Table 1) Of 524 patients treated with AmBd, the median number of days on treatment was 11 (interquartile range (IQR), 6–14 days). The CFR for those on AmBd was 25% (134/524). Overall in-hospital CFR was 29% (187/642) (academic: 29% [103/352] vs. non-academic: 29% [84/290], p = 0.935).
Footnote: AmBd: amphotericin B deoxycholate. *Other reason: 10 (8%) no antifungal therapy was given; 3 (3%) AmBd was out of stock
Prevalence of AmBd-related toxicities
Prior to receiving AmBd therapy, there were 91 patients with pre-existing anemia, 101 with hypokalemia and 42 with renal dysfunction. During AmBd therapy, an additional 12% of patients (52/433) developed anemia, 39% (163/423) developed hypokalemia and 30% (144/482) developed nephrotoxicity. Of those who were optimally monitored for AmBd-related toxicities (and including those with pre-existing anemia, hypokalemia and nephrotoxicity), 54% (77/142) developed anemia, 71% (167/235) developed hypokalemia and 55% (127/232) developed nephrotoxicity (Table 2). Among those optimally monitored, the proportion of patients who developed toxicities was similar at academic vs. non-academic ES sites (p = 0.363 for anemia, p = 0.717 for hypokalemia and p = 0.101 for nephrotoxicity) and did not differ significantly if those with pre-existing anemia, hypokalemia and nephrotoxicity were excluded. Most cases of new-onset nephrotoxicity (57%; 82/144) developed during the second week of AmBd therapy. In most cases, the severity of complications was mild to moderate. Among those optimally monitored, potentially life-threatening (grade 4) toxicities occurred among 17% (13/77) of patients with anemia, 5% (8/167) of patients with hypokalemia and 6% (7/127) of patients with nephrotoxicity. Severe (grade 3) nephrotoxicity and anemia was significantly higher among patients treated with AmBd who had pre-existing nephrotoxicity and anemia (57% vs. 25% for grade 3 nephrotoxicity, p = 0.03; and 22% vs. 7% for grade 3 anemia, p = 0.03) (S1 Table).
Adherence to recommendations for prevention of AmBd-related toxicities
While just under two-thirds of cases (64%, 333/524) had Hb, K and Cr tests performed at baseline, optimal pre-emptive hydration was administered to 40% (211/524), optimal oral KCl supplementation to 19% (101/524) and optimal IV KCl supplementation to 14% (72/524) of patients. (Table 3) Patients treated with AmBd at academic ES sites were more likely to receive optimal IV KCl supplementation than at non-academic sites (20%, 57/286 vs. 6%, 15/238, p<0.001).
Adherence to recommendations for monitoring for AmBd-related toxicities
The majority of patients had daily fluid monitoring (86%, 452/524). However, only 45% (235/524) and 44% (232/524) of patients had serum K and Cr levels checked bi-weekly, whilst less than one third of patients had weekly monitoring of Hb levels. (Table 3) Patients at academic ES sites were significantly more likely to have all four aforementioned parameters monitored than those at non-academic ES sites (p<0.001). (S2 Table)
Case-fatality ratio
On multivariable analysis, only a GCS score of 15 and optimal pre-emptive hydration during AmBd treatment was significantly associated with in-hospital survival. (Table 4) Among those optimally monitored for AmBd-related toxicities, there was also no significant difference in outcome between those who developed nephrotoxicity, hypokalemia or anemia (whether or not the patients with baseline anemia, hypokalemia or nephrotoxicity were included in the analysis) (Table 2). In addition, there was no difference in outcome by ES site category, sex, CD4 count, ART use, pre-existing anemia, pre-existing hypokalemia or pre-existing renal impairment. The exact cause of death for the 25% who died after receiving AmBd treatment was not determined.
Physician knowledge and behavior
Forty-two physicians, ranging in experience from interns to certified specialists, were interviewed at 20 of the 25 ES sites (this included at least one hospital from each of South Africa’s 9 provinces). (Table 1) Half the physicians were from academic sites and the other half from non-academic sites. At academic sites, most interviews were conducted with specialist trainees (registrars; 38% [8/21]) while non-specialist medical officers were most often interviewed at non-academic sites (48%, 10/21). There was no significant difference in responses between physicians at academic vs. non-academic sites. While 67% (28/42) reported that they were aware of any guideline for the management of cryptococcal disease, only 26% (11/42) were aware of the WHO Rapid Advice guidelines published a year earlier. The majority (38/42, 95%) indicated that they used AmBd as first-line management and 93% (39/42) were aware of potential toxicities associated with its use. When asked about interventions to prevent AmBd toxicities, 79% (33/42) reported prescribing pre-emptive hydration, 71% (30/42) said that they checked baseline Hb levels, 90% (40/42) reported checking baseline serum Cr and K and 71% (30/42) said that they prescribed routine electrolyte supplementation. However, when asked to specify the type of electrolyte supplementation, 40% (17/42) said that they prescribed oral KCl daily and only 5% (2/42) prescribed IV KCl. Almost all (40/42) claimed to monitor serum Cr and K levels during AmBd treatment, though only 60% (24/40) ordered these tests twice a week.
Discussion
While the vast majority of South African patients with cryptococcosis in this urban, hospital-based observational study were treated with AmBd, the overall in-hospital CFR was high. A GCS score of 15 and pre-emptive hydration during AmBd treatment was associated with in-hospital survival. AmBd-related toxicities developed frequently during treatment, including half of patients who developed nephrotoxicity, but most toxicities were graded mild to moderate. Almost two-thirds of patients had baseline laboratory tests performed but less than half received pre-emptive hydration and less than a fifth were prescribed pre-emptive potassium supplementation. Fluid monitoring was well implemented though less than half of patients had appropriate monitoring laboratory tests ordered. These findings contrast starkly with physician perceptions of management of AmBd toxicities. While most physicians prescribed AmBd as first-line therapy and were aware of the potential toxicities associated with its use, less than a third were aware of published recommendations to mitigate these toxicities.
Eighty per cent of patients admitted with cryptococcosis received AmBd induction therapy in 2012–2013. This is a substantial improvement since 2008 when only 30% of patients received AmBd[11, 12]. Possible reasons for increased use of AmBd include a reduction in the cost of AmBd, inclusion in the South African hospital-level essential medicines list, improved availability in hospital pharmacies and publication of local guidelines on cryptococcal disease management [7, 8, 23]. However, many patients still do not receive adequate induction-phase treatment due to the additional nursing time required to manage an IV infusion, the need to hospitalize patients while receiving AmBd, the perception that AmBd-related toxicities are unmanageable and the need for access to laboratory services to monitor for AmBd-related toxicities.
Among patients on AmBd therapy, those who were given a liter of normal saline intravenously prior to each dose of AmBd were 70% more likely to survive than those who did not receive optimal pre-emptive hydration, even when controlling for altered mental status which is a major contributor to acute mortality [3, 4]. This intervention may improve survival by decreasing AmBd-related nephrotoxicity and electrolyte abnormalities [16, 19, 24]. Unfortunately, we could not test this hypothesis by including nephrotoxicity, hypokalemia and anemia into our multivariate model as monitoring for these laboratory-diagnosed toxicities was very poor. We did not show any difference in in-hospital mortality among those who were both optimally monitored for AmBd-related toxicities and developed toxicities. This is not surprising since these patients were potentially already receiving superior care than those with no or suboptimal monitoring for AmBd-related toxicities. Eighty per cent of physicians reported giving pre-emptive hydration to patients prior to each dose of AmBd; however, in clinical practice this was only delivered 40% of the time.
In keeping with other studies, we found a high prevalence of AmBd-related toxicities; however, only 24% of these toxicities were classified as severe or life-threatening [3, 17, 25]. Half of the patients developed nephrotoxicity; two-thirds developed hypokalemia; and half developed anemia. The nephrotoxicity reported in this study was in keeping with experiences from elsewhere: this usually occurred in the second week of AmBd treatment and was mostly reversible if diagnosed and treated appropriately. We report a much higher prevalence of hypokalemia in this observational study than has been reported in clinical trial settings, where electrolyte supplementation was standardized [16]. Only 40% of interviewed physicians reported routinely administering KCl and in practice, very few patients actually received this supplementation (19% oral and 14% IV). Physicians may be reluctant to use KCl supplementation for fear of hyperkalemia and its complications. However, the high prevalence of hypokalemia during AmBd treatment in this and other studies suggests that this concern is unfounded, especially if laboratory tests are ordered as recommended [16, 18, 19]. Anemia is a common finding among HIV-infected hospitalized patients and a common toxicity associated with AmBd therapy [16, 26]. Of the patients with optimal Hb monitoring, a large proportion (54%) developed anemia during AmBd treatment. Severe, potentially life-threatening anemia, which requires urgent blood transfusion, was fortunately rare.
Despite adequate knowledge of the disease management guidelines by interviewed physicians, actual implementation of recommendations for preventing and monitoring for AmBd toxicities was particularly poor. Evidence-based guidelines for patient management are useful documents but will only impact on patient outcome if physicians are aware of them and if all members of the clinical team adhere to them. Although local guidelines to reduce AmBd-related toxicities have been developed, targeted training may be required to educate hospital-based pharmacists, nurses and doctors. It may also be useful for hospital pharmacists to attach step-by-step prevention and monitoring recommendations to the prescription chart when AmBd is released by the hospital pharmacy.
Use of liposomal amphotericin B in South Africa is currently prohibitive due to the high cost (approx. US$160 per 50 mg vial vs. approx. US$2.55 per 50 mg vial for AmBd). Liposomal amphotericin B is currently available through Gilead’s Visceral Leishmaniasis Treatment Expansion Program at a price of approx. US$16 per 50 mg vial. If a reduced price could also be negotiated for cryptococcosis in resource-limited settings, liposomal amphotericin B could potentially be used as a second-line agent in the subset of patients (approximately 25%) that develop AmBd-related nephrotoxicity. Liposomal amphotericin B is a much safer agent with fewer toxicities and use of this agent would eliminate the need for an intensive toxicity prevention and monitoring regimen [27, 28].
There were limitations in determining the presence of toxicities in this observational study, as laboratory testing was not performed according to a schedule. Many patients did not have appropriate tests ordered, even though all the hospitals in the study had access to laboratory facilities. Therefore, without optimal monitoring, we could not determine the impact that these toxicities had on patient outcomes as it is likely that patients who developed clinical signs of toxicities were more likely to be tested. We did not collect data on whether serial therapeutic lumbar punctures, which benefit patients with raised intracranial pressure and may be indicators of better patient care, were performed [29]. Our data showed that patients who had an initial intracranial CSF opening pressure measurement had better outcomes. Although this was not significant, it may indicate better patient care.
A limitation of conducting separate physician interviews was that those interviewed may not have been the same physicians treating the patients in the study. However, all physicians reported being directly involved in day-to-day management of patients with cryptococcosis. Other reasons could include recall bias, physicians’ orders not being directly followed or various institutional barriers to best practice, e.g. pharmacy stock outs.
A strength of this observational study was the large geographic area that it covered, as the ES sites, where the clinical data were collected, treat on average a quarter of the patients diagnosed with cryptococcosis in the country [12]. The aggregated results mask the excellent care provided at some hospital settings as well as the poor management of patients at others.
Although prevention or early diagnosis of cryptococcal disease among HIV-infected patients should be the primary focus from a public health perspective, our data show that once patients are admitted to hospital with cryptococcosis, there are still many areas of management that could be improved upon. As AmBd forms the backbone of an induction-phase regimen for CM, AmBd-related toxicities need to be prevented and properly managed. This study highlights a need for adherence to AmBd toxicity prevention, monitoring and management recommendations, as toxicities occurred frequently but are potentially preventable with adequate monitoring and supplemental therapies.
Supporting Information
S1 Checklist. STROBE Checklist of items that should be included in reports of cross-sectional studies: PNTD-D-16-00494R1: Prevalence and hospital management of amphotericin B deoxycholate-related toxicities during treatment of HIV-associated cryptococcal meningitis in South Africa.
https://doi.org/10.1371/journal.pntd.0004865.s001
(DOC)
S1 Table. Grading of toxicities among patients treated with amphotericin B deoxycholate and optimally monitored* during treatment: a comparison between those who had existing toxicity at baseline and those who developed new onset toxicity during treatment.
Footnote: *Optimal monitoring: hemoglobin measured weekly whilst on amphotericin B deoxycholate (AmBd) therapy; or K or Cr measured biweekly whilst on AmBd therapy.
https://doi.org/10.1371/journal.pntd.0004865.s002
(DOCX)
S2 Table. Comparison of adherence to recommendations for prevention and monitoring of amphotericin B deoxycholate-related toxicities at academic versus non-academic hospitals (n = 524).
https://doi.org/10.1371/journal.pntd.0004865.s003
(DOCX)
Acknowledgments
This work has been presented in part at the 6th South African AIDS Conference, 18–21 June 2013, in Durban, South Africa and in part, at the Federation of Infectious Diseases Societies of South Africa, FIDSSA 5th joint congress, 10–12 October 2013, in KwaZulu-Natal, South Africa.
We would like to thank all clinical and laboratory staff throughout South Africa for submitting case reports and isolates for the GERMS-SA national surveillance program, as well as all the patients who agreed to provide further clinical details and the surveillance officers who collected the additional treatment data.
The GERMS-SA team 2012–2013
Head of unit: Dr Vanessa Quan vanessaq@nicd.ac.za
Carel Haumann, Patricia Hanise, Dania Perez, Pieter Ekermans; Sandeep Vasaikar (Eastern Cape); Anwar Hoosen, Dominique Goedhals, Justyna Wojno, Madeleine Pieters, Ute Hallbauer (Free State); Alan Karstaedt, Caroline Maluleka, Charl Verwey, Charles Feldman, Jeannette Wadula, Kathy Lindeque, Maphoshane Nchabeleng, Nicolette du Plessis, Norma Bosman, Ranmini Kularatne, Ruth Lekalakala, Sharona Seetharam, Theunis Avenant, Trusha Nana, Vindana Chibabhai, Jeane Cloete, Gary Reubenson, Sheba Varughese, Moamokgethi Moshe, Bonnie Maloba (Gauteng); Asmeeta Burra, Fathima Naby, Halima Dawood, Koleka Mlisana, Lisha Sookan, Praksha Ramjathan, Prasha Mahabeer, Romola Naidoo, Sumayya Haffejee, Yacoob Coovadia, Adhil Marajh, Dawid Brits, Dhamiran Naidoo, Mandlenkosi Chamane, Sushi Pather, Khatija Dawood, Roshini Bridgemohan (KwaZulu Natal); Andries Dreyer, Ken Hamese, Ngoaka Sibiya, Phaswe Maredi (Limpopo); Greta Hoyland, Jacob Lebudi, Barry Spies (Mpumalanga); Dhamiran Naidoo, Eunice Weenink; Riezaah Abrahams, Pieter Jooste, Stan Harvey (Northern Cape); Ebrahim Variava, Eduard Silberbauer, Andrew Rampe, Lino Sono (North West); Catherine Samuel, Preneshni Naicker, Elizabeth Wasserman, Brian Eley, James Nuttal, Louise Cooke, Heather Finlayson, Helena Rabie, Andrew Whitelaw (Western Cape); Adrian Brink, Charlotte Sriruttan, Inge Zietsman, Maria Botha, Peter Smith, Suzy Budavari, Xoliswa Poswa (AMPATH); Chetna Govind, Keshree Pillay (LANCET); Marthinus Senekal (PathCare); Cynthia Whitney, Jennifer Verani, Stephanie Schrag, Anne Schuchat (CDC, Atlanta, USA); Keith Klugman (Emory University, USA); Verushka Chetty, Rindi Magobo, Gloria Zulu, David Solomon, Brian Nemukula, Irene Kachomba, Ashika Singh-Moodley, Refilwe Letsoela, Florah Motsai, Crystal Viljoen, Zazi Molebatsi, Peggy Wilson, Serisha Naicker, Elias Khomane, Notsikelelo Matiwane, Yoliswa Bacela, Andriena Saif, Boniwe Makwakwa, Mabatho Moerani, Rubeina Badat, Sophia Tshaka, Tsidiso Maphanga, Ananta Nanoo, Anne von Gottberg, Arvinda Sooka, Cecilia Miller, Cheryl Cohen, Claire von Mollendorf, Karen Keddy, Linda de Gouveia, Linda Erasmus, Languta Sibiya, Mmakgomo Rakhudu, Marshagne Smith, Melony Fortuin-de Smidt, Nazir Ismail, Nelesh Govender, Nevashan Govender, Olga Perovic, Penny Crowther-Gibson, Ruth Mpembe, Sarona Lingana, Sonwabo Lindani, Susan Meiring, Vanessa Quan (NICD).
GERMS-SA Surveillance Officers: Sandisiwe Joyi (Eastern Cape); Khasiane Mawasha (Free State); Anna Motsi, Busi Mbatha, Joy Appolis, Dikeledi Leshaba, Fiona Timber, Hazel Mzolo, Mokupi Manaka, Molly Morapeli, Ophtia Kaoho, Phindile Ngema, Rachel Nare, Venesa Kok, Vusi Ndlovu, Zodwa Kgaphola (Gauteng); Indran Naidoo, Nkosinathi Mbhele, Nokuthula Nzuza, Michelle Moodley, Ulenta Chetty (KwaZulu Natal); Maria Mokwena (Limpopo); Sunnieboy Njikho (Mpumalanga); Matsheko Siyaka (Northern Cape); Joyce Tsotsotso (North West); Cheryl Mentor, Elizabeth Sharon Jerome, Nazila Shalabi, Priscilla Mouton (Western Cape)
Disclaimer
The contents of this study are solely the responsibility of the authors and do not necessarily represent the official views of the National Institute for Communicable Diseases, a Division of the National Health Laboratory Service or the U.S. Centers for Disease Control and Prevention (CDC).
Author Contributions
Conceived and designed the experiments: NPG SM. Performed the experiments: SM NPG MFdS. Contributed reagents/materials/analysis tools: SM MFdS RK HD NPG. Wrote the paper: SM NPG MFdS RK HD.
References
- 1. Park BJ, Shetty S, Ahlquist A, Greenbaum A, Miller JL, Motsi A, et al. Long-term follow-up and survival of antiretroviral-naive patients with cryptococcal meningitis in the pre-antiretroviral therapy era, Gauteng Province, South Africa. Int JSTD AIDS. 2011;22(4):199–203.
- 2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525–30. pmid:19182676
- 3. Kambugu A, Meya DB, Rhein J, O'Brien M, Janoff EN, Ronald AR, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008;46(11):1694–701. pmid:18433339
- 4. Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: Implications for improving outcomes. Clin Infect Dis. 2014;58(5):736–45. pmid:24319084
- 5. Loyse A, Dromer F, Day J, Lortholary O, Harrison TS. Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrob Chemother. 2013;68(11):2435–44. pmid:23788479
- 6. Govender NP, Roy M, Mendes JF, Zulu TG, Chiller TM, Karstaedt AS. Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa. HIV Med. 2015;16(8):468–76. pmid:25689352
- 7. HIV Clinicians Society of South Africa, Govender NP, Meintjes G, Bicanic T, Dawood H, Harrison T, et al. Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons: 2013 update SAJHIVMed. 2014;14(2):76–86.
- 8. McCarthy KM, Meintjes G, Arthington-Skaggs B, Bicanic T, Cotton M, Chiller T, et al. Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients. SAJHIVMed. 2007;Spring edition:25–35.
- 9. Day JN, Chau TT, Wolbers M, Mai PP, Dung NT, Mai NH, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368(14):1291–302. pmid:23550668
- 10. Govender NP, Meintjes G, Banoo S. Access to flucytosine for HIV-infected patients with cryptococcal meningitis—an urgent need. SAMJ. 2014;104(9):594–5. pmid:26307779
- 11.
GERMS-SA Annual Report 2008 [Internet]. 2009. Available from: http://nicd.ac.za/?page=germs-sa&id=97.
- 12.
GERMS-SA Annual Report 2010 [Internet]. 2011. Available from: http://nicd.ac.za/?page=germs-sa&id=97.
- 13.
Malahyde Information Systems. SA Electronic Package Inserts: Fungizone Intravenous. 2005.
- 14. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12(2):308–29. pmid:2184499
- 15. Ochieng PO, McLigeyo SO, Amayo EO, Kayima JK, Omonge EO. Nephrotoxicity of amphotericin B in the treatment of cryptococcal meningitis in acquired immunodeficiency syndrome patients. East AfrMed J. 2009;86(9):435–41.
- 16. Bicanic T, Bottomley C, Loyse A, Brouwer AE, Muzoora C, Taseera K, et al. Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. Antimicrob Agents Chemother. 2015;59(12):7224–31. pmid:26349818
- 17. Thakur CP, Kumar A, Mitra DK, Roy A, Sinha AK, Ranjan A. Improving outcome of treatment of kala-azar by supplementation of amphotericin B with physiologic saline and potassium chloride. AmJTropMed Hyg. 2010;83(5):1040–3.
- 18. Echevarria J, Seas C, Cruz M, Chavez E, Campos M, Cieza J, et al. Oral rehydration solution to prevent nephrotoxicity of amphotericin B. AmJTropMed Hyg. 2006;75(6):1108–12.
- 19. Bahr NC, Rolfes MA, Musubire A, Nabeta H, Williams DA, Rhein J, et al. Standardized electrolyte supplementation and fluid management improves survival during amphotericin therapy for cryptococcal meningitis in resource-limited settings. Open Forum Infect Dis. 2014;1(2):ofu070. pmid:25734140
- 20.
World Health Organisation. Rapid Advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva, Switzerland: World Health Organisation, 2011.
- 21. Meiring ST, Quan VC, Cohen C, Dawood H, Karstaedt AS, McCarthy KM, et al. A comparison of cases of paediatric-onset and adult-onset cryptococcosis detected through population-based surveillance, 2005–2007. AIDS. 2012;26(18):2307–14. pmid:22739390
- 22.
Division of AIDS, Regulatory Support Centre. Division of AIDS Table for Grading the Severty of Adult and Pediatric Adverse Events. Version 1.0 December 2004; Clarification August 20092014.
- 23. Loyse A, Thangaraj H, Easterbrook P, Ford N, Roy M, Chiller T, et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis. 2013;13(7):629–37. pmid:23735626
- 24. Lewis RE, Viale P. Update on Amphotericin B Pharmacology and Dosing for Common Systemic Mycoses. Curr Fung Infect Reports. 2012;6(4):349–57.
- 25. Bicanic T, Wood R, Meintjes G, Rebe K, Brouwer A, Loyse A, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis. 2008;47(1):123–30. pmid:18505387
- 26. Kerkhoff AD, Lawn SD, Schutz C, Burton R, Boulle A, Cobelens FJ, et al. Anemia, Blood Transfusion Requirements and Mortality Risk in Human Immunodeficiency Virus-Infected Adults Requiring Acute Medical Admission to Hospital in South Africa. Open Forum Infect Dis. 2015;2(4):ofv173. pmid:26730391
- 27. Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. 1997;11(12):1463–71. pmid:9342068
- 28. Loo AS, Muhsin SA, Walsh TJ. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. Expert Opin Drug Saf. 2013;12(6):881–95. pmid:23931455
- 29. Rolfes MA, Hullsiek KH, Rhein J, Nabeta HW, Taseera K, Schutz C, et al. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin Infect Dis. 2014;59(11):1607–14. pmid:25057102